4.7 Article

Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 141, Issue 4, Pages 1182-1190

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2018.02.006

Keywords

Innate type 2 immunopathology; allergic inflammation; asthma; eosinophilic esophagitis; aspirin-exacerbated respiratory disease; innate lymphoid cells; innate immune cells; eicosanoids; cysteinyl leukotrienes; prostaglandins; prostacyclins

Funding

  1. National Institutes of Health [AI078908, AI095219, AT002782, AI082369, HL111113, HL117945]

Ask authors/readers for more resources

Type 2 immunopathology is a cardinal feature of allergic diseases and involves cooperation between adaptive immunity and innate effector responses. Virtually all cell types relevant to this pathology generate leukotriene and/or prostaglandin mediators that derive from arachidonic acid, express receptors for such mediators, or both. Recent studies highlight prominent functions for these mediators in communication between the innate and adaptive immune systems, as well as amplification or suppression of type 2 effector responses. This review focuses on recent advances and insights, and highlights existing and potential therapeutic applications of drugs that target these mediators or their receptors, with a special emphasis on their regulation of the innate and adaptive lymphocytes relevant to type 2 immunopathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available